Your browser doesn't support javascript.
loading
HIV variability and perspectives for a vaccine.
Verani, P; Buttò, S; Taddeo, B; Federico, M; Rossi, G B.
Afiliação
  • Verani P; Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy.
Vaccine ; 11(5): 542-4, 1993.
Article em En | MEDLINE | ID: mdl-8488707
An overview of efforts to induce neutralizing antibodies in order to develop an effective vaccine against AIDS is presented. The principal Neutralizing Determinant (PND) on the HIV-1 envelope is described. PND variability and the induction of neutralizing antibodies by synthetic peptides representing PND are discussed. The use of a cocktail of different peptides representing the PND sequences of the majority of HIV-1 isolates, as well as the construction of hybrid immunogens containing PND of several viral isolates, could overcome the problems related to PND variability. A different approach based on the possibility of inducing a type of intracellular immunity is also discussed: a cellular clone (F12) obtained in our laboratory from Hut-78 cells infected with supernatant of cultured lymphocytes from an HIV-infected patient, does not release viral particles despite the presence of a full-length HIV-1 provirus. Moreover, F12 cells are fully resistant against superinfection with any HIV-1 or HIV-2 isolates. We are now attempting to reproduce the homologous viral interference by transferring the F12/HIV genome of the clone into HIV-susceptible cells in order to render these cells resistant to HIV infection.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Fragmentos de Peptídeos / Anticorpos Anti-HIV / Proteína gp120 do Envelope de HIV / HIV-1 / Vacinas contra a AIDS Idioma: En Ano de publicação: 1993 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Fragmentos de Peptídeos / Anticorpos Anti-HIV / Proteína gp120 do Envelope de HIV / HIV-1 / Vacinas contra a AIDS Idioma: En Ano de publicação: 1993 Tipo de documento: Article